Alper, 1989, New Eng J Med, 321, 708, 10.1056/NEJM198909143211103
, . 1988. Genetics of non-responders to hepatitis B surface antigen and possible ways of circumventing non-response. In: editor. Viral hepatitis and liver disease. New York: Alan R Liss. pp 714-716.
Ascherio, 2001, New Eng J Med, 344, 327, 10.1056/NEJM200102013440502
Autram, 2004, Science, 305, 205, 10.1126/science.1100600
Banatvala, 1996, London: Royal Coll Physicians, 1
Beckebaum, 2002, Rev Med Virol, 12, 297, 10.1002/rmv.359
Canada Communicable Disease Report, 1992, Can Commun Dis Rep, 18-7, 49
Canada Medical Association, 1993, Can Med Assoc J, 149, 314
Carman, 1990, Lancet, 336, 325, 10.1016/0140-6736(90)91874-A
Confavreux, 2001, New Eng J Med, 344, 319, 10.1056/NEJM200102013440501
Dahmen, 2002, J Med Virol, 66, 452, 10.1002/jmv.2165
European Consensus Group on Hepatitis B Immunity, 2002, Lancet, 355, 561
Francois, 2001, Vaccine, 19, 3799, 10.1016/S0264-410X(01)00108-6
Gonclaves, 2004, Virology, 326, 20, 10.1016/j.virol.2004.04.042
Gout, 1998, Rev Neurol (Paris), 154, 205
Heathcote, 1999, Hepatology, 30, 531, 10.1002/hep.510300208
Hernan, 2004, Neurology, 63, 838, 10.1212/01.WNL.0000138433.61870.82
Hsu, 1999, Hepatology, 30, 1312, 10.1002/hep.510300511
Jarrosson, 2004, Vaccine, 22, 3789, 10.1016/j.vaccine.2004.02.046
Jefferson, 1998, Brit Med J, 317, 159, 10.1136/bmj.317.7152.159
Krusall, 1992, J Exp Med, 175, 495, 10.1084/jem.175.2.495
1999. Testimony before the US house of representatives committee on government reform subcommittee on criminal justice, drug policy and human resources. www.cdc.gov/ncidod/diseases/hepatitis accessed May 26th 2005.
McDermott, 1999, Vaccine, 17, 330, 10.1016/S0264-410X(98)00203-5
Michel, 2001, Vaccine, 19, 2395, 10.1016/S0264-410X(00)00461-8
Milich, 1986, J Immunol, 137, 315, 10.4049/jimmunol.137.1.315
, , . 1997. Hepatitis B virus (HBV) mutants among mothers and infants and chronic hepatitis B infection. In: , , , editors. Viral Hepatitis and Liver Disease. Torino: Minerva Medica. pp 132-134.
Nainan, 2002, J Med Virol, 68, 319, 10.1002/jmv.10206
Oon, 1995, Vaccine, 13, 699, 10.1016/0264-410X(94)00080-7
Oon, 1996, Lancet, 348, 1524, 10.1016/S0140-6736(05)65950-8
Tourbah, 1999, Neurology, 53, 396, 10.1212/WNL.53.2.396
WER, 1999, Wkly Epidemiol Rec, 72, 149
Whittle, 2002, Brit Med J, 325, 569, 10.1136/bmj.325.7364.569
Wilson, 1999, Vaccine, 17, 973, 10.1016/S0264-410X(98)00313-2
Wraith, 2003, Lancet, 362, 1659, 10.1016/S0140-6736(03)14802-7
Zuckerman, 1996, J Med Virol, 50, 283, 10.1002/(SICI)1096-9071(199612)50:4<283::AID-JMV1>3.0.CO;2-4
Zuckerman, 1998, Viral Hepatitis Rev, 4, 43
Zuckerman, 1999, J Med Virol, 58, 193, 10.1002/(SICI)1096-9071(199907)58:3<193::AID-JMV1>3.0.CO;2-X
Zuckerman, 2002, Expert Rev Vaccine, 1, 141, 10.1586/14760584.1.2.141
Zuckerman, 1992, Brit Med J, 305, 1158, 10.1136/bmj.305.6862.1158
